The TNXP chart settings shown below allow you to select time intervals of 1 min, 30 mins, an hour or by day - week - month. There is also the ability to change the TNXP chart style to candles, hollow candles, bars, lines or add various indicators. You can even add a symbol and compare history.
The TNXP stock resources shown below were gathered to cut back on time by allowing you to visit multiple sites at once. For your convenience each link clicked will open in a window. In addition to the individual links there is a button at the bottom that will allow you to open all the links at the same time. Note opening all links at once may not work with all browsers. Some browsers block multiple windows, to resolve this please allow that site to use pop-ups.
|View TNXP Detailed Price Forecast - CNN Money||View TNXP Detailed Summary - Google Finance|
|View TNXP Detailed Summary - Yahoo! Finance||View TNXP Stock Research & Analysis - Zacks.com|
|View TNXP Trends & Analysis - Trade-Ideas||View TNXP Major Holders - Barrons|
|View TNXP Call Transcripts - NASDAQ||View TNXP Breaking News & Analysis - Seeking Alpha|
|View TNXP Annual Report - CompanySpotlight.com||View TNXP OTC Short Report - OTCShortReport.com|
|View TNXP Fundamentals - TradeKing||View TNXP SEC Filings - Bar Chart|
|View Historical Prices for TNXP - The WSJ||View Performance/Total Return for TNXP - Morningstar|
|View the Analyst Estimates for TNXP - MarketWatch||View the Earnings History for TNXP - CNBC|
|View the TNXP Earnings - StockMarketWatch||View TNXP Buy or Sell Recommendations - MacroAxis|
|View the TNXP Bullish Patterns - American Bulls||View TNXP Short Pain Metrics - ShortPainBot.com|
|View TNXP Stock Mentions - StockTwits||View TNXP Stock Mentions - PennyStockTweets|
|View TNXP Stock Mentions - Twitter||View TNXP Investment Forum News - Investor Hub|
|View TNXP Stock Mentions - Yahoo! Message Board||View TNXP Stock Mentions - Seeking Alpha|
|View Insider Transactions for TNXP - SECform4.com||View Insider Transactions for TNXP - Insider Cow|
|View TNXP Major Holdings Summary - CNBC||View Insider Disclosure for TNXP - OTC Markets|
|View Insider Transactions for TNXP - Yahoo! Finance||View Institutional Holdings for TNXP - NASDAQ|
|View TNXP Stock Insight & Charts - FinViz.com||View TNXP Investment Charts - StockCharts.com|
|View TNXP Stock Overview & Charts - BarChart||View TNXP User Generated Charts - Trading View|
Bullish Insiders Bought More Of These Stocks In June
Posted on Wednesday June 20, 2018
Generally, insiders buying more shares in their own firm sends a bullish signal. A research published in The MIT Press (1998) concluded that stocks following insider buying outperformed the marketRead More...
Tonix Pharmaceuticals Presented New Data Related to Suicidal Ideation and Behaviors in Military-Related PTSD from the Phase 2 AtEase Study at the American Society of Clinical Psychopharmacology
Posted on Thursday May 31, 2018
Tonix Pharmaceuticals Holding Corp. (TNXP) (Tonix), presented data from the Phase 2 AtEase study of Tonmya®* (cyclobenzaprine HCl sublingual tablets) for the treatment posttraumatic stress disorder (PTSD). “There are several examples in major psychiatric disorders in which pharmacological treatment of the underlying disorder may decrease suicidal behaviors,” said Gregory Sullivan, M.D., Chief Medical Officer of Tonix.
Tonix Pharmaceuticals to Present at the 2018 BIO International Convention
Posted on Wednesday May 30, 2018
NEW YORK, May 30, 2018-- Tonix Pharmaceuticals Holding Corp., announced today that Seth Lederman, M.D., President and Chief Executive Officer of Tonix, will present an overview of the Company, focusing ...
Tonix Pharmaceuticals Holding Corp. (TNXP) (Tonix), announced preliminary results from a Phase 1 pivotal multiple-dose bridging pharmacokinetic study of Tonmya®*, or TNX-102 SL, which is required to support the 505(b)(2) NDA submission for TNX-102 SL, using AMRIX®# (cyclobenzaprine HCl extended-release [ER]) capsules) as the reference listed drug (RLD). The design of this study had been previously accepted by the FDA. Specifically, the study compared the plasma levels and the safety profile of TNX-102 SL 5.6 mg (administered as 2 x 2.8 mg tablets) taken sublingually versus the recommended dose of the RLD, AMRIX 30 mg ER capsule, over 20 consecutive days of daily dosing under fasting conditions in healthy subjects aged 18-65 years old. Tonmya is in Phase 3 development for the bedtime treatment of military-related posttraumatic stress disorder (PTSD) and TNX-102 SL has an effective IND for a Phase 2 efficacy study for the treatment of agitation in Alzheimer’s disease.